CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

The Lancet Oncology

Volumn 9, Issue 2, 2008, Pages 132-138

  Hess, Viviane ^a   Glimelius, Bengt ^b   Grawe, Philipp ^a   Dietrich, Daniel ^c   Bodoky, György ^d   Ruhstaller, Thomas ^e   Bajetta, Emilio ^f   Saletti, Piercarlo ^g   Figer, Arie ^h   Scheithauer, Werner ⁱ   Herrmann, Richard ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d Szent Laszlo Hospital   (Hungary)

^e Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^f National Institute for Cure and Study of Tumours   (Italy)

^g ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^h Sourasky Medical Centre   (Israel)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; GEMCITABINE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HYPOTHESIS; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38549176328     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70001-9     Document Type: Article

References (21)

1. Boeck S., Stieber P., Holdenrieder S., Wilkowski R., and Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70 (2006) 255-264
2. Koprowski H., Herlyn M., Steplewski Z., and Sears H. Specific antigen in serum of patients with colon carcinoma. Science 212 (1981) 53-55
3. Gogas H., Lofts F., Evans T., Daryanani S., and Mansi J. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?. Br J Cancer 77 (1998) 325-328
4. Halm U., Schumann T., Schiefke I., Witzigmann H., Mossner J., and Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82 (2000) 1013-1016
5. Ishii H., Okada S., Sato T., et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44 (1997) 279-283
6. Ko A., Hwang J., Venook A., Abbruzzese J., Bergsland E., and Tempero M. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93 (2005) 195-199
7. Maisey N., Norman A., Hill A., Massey A., Oates J., and Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93 (2005) 740-743
8. Stemmler J., Stieber P., Szymala A., et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?. Onkologie 26 (2003) 462-467
9. Ziske C., Schlie C., Gorschluter M., et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89 (2003) 1413-1417
10. McShane L., Altman D., Sauerbrei W., Taube S., Gion M., and Clark G. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (2005) 9067-9072
11. Locker G., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313-5327
12. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (2007) 2212-2217
13. La'ulu S., and Roberts W. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol 127 (2007) 1-5
14. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
15. Anderson J., Cain K., and Gelber R. Analysis of survival by tumor response. J Clin Oncol 1 (1983) 710-719
16. Buyse M., and Piedbois P. On the relationship between response to treatment and survival time. Stat Med 15 (1996) 2797-2812
17. Chua Y., and Cunningham D. Chemotherapy for advanced pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006) 327-348
18. Micke O., Bruns F., Kurowski R., et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 90-97
19. Bucher H., Guyatt G., Cook D., Holbrook A., and McAlister F. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 282 (1999) 771-778
20. Buyse M., Thirion P., Carlson R., Burzykowski T., Molenberghs G., and Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356 (2000) 373-378
21. Altman D., and De Stavola B. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13 (1994) 301-341